Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master Protocol for Multiple Interventions in Chronic Weight Management
NCT06143956Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Hormonal Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of mazdutide, eloralintide, tirzepatide, naperiglipron, macupatide in obesity, sponsored by Eli Lilly and Company. Started Nov 2023; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06143956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143956.